Efficiency and Safety of the Prolonged Use of Heat and Moisture Exchangers in ICU
Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · May 10, 2024
Trial Information
Current as of November 08, 2025
Recruiting
Keywords
ClinConnect Summary
The FILTRex trial is studying the use of special filters called Heat and Moisture Exchangers (HMEs) in patients who are on mechanical ventilation in the Intensive Care Unit (ICU). These filters help to warm and moisten the air that patients breathe, which can be important for their recovery. This trial will compare the effects of using these filters for a longer duration of 72 hours versus the standard 24 hours, to see which is more effective and safe for preventing Ventilator Associated Pneumonia (VAP), a common lung infection in ventilated patients.
To participate in this study, patients need to be at least 18 years old, be in the ICU, and expect to be on mechanical ventilation for at least 72 hours. They should also have a certain score that indicates they are not showing signs of a lung infection at the start of the trial. Participants will have the chance to receive either the longer or standard duration of HME use, and their health will be closely monitored throughout the study. This research aims to improve care for critically ill patients, and your involvement could help make a difference for future patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years
- • 2. In-patient in ICU and expected to stay \> 3 days
- • 3. Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation ≥ 72h
- • 4. Clinical Pulmonary Infection score (CPIS) less than six at the baseline 5 No history and symptoms of aspiration at the baseline
- Exclusion Criteria:
- • 1. Suspected pulmonary infection on admission and in the first 48 hours of mechanical ventilation
- • 2. Pregnancy
- • 3. Acute respiratory distress syndrome
- • 4. Body temperature \< 32°C
- • 5. Airway bleeding or other contraindications for the use of HME
- • 6. An early decision of treatment withdrawal
About Charles University, Czech Republic
Charles University, located in the Czech Republic, is a prestigious institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct innovative research that aims to improve patient outcomes and contribute to the global medical community. With a focus on ethical standards and rigorous scientific methodologies, Charles University collaborates with various stakeholders to explore new therapies and enhance healthcare practices, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Prague, česká Republika, Czechia
Prague, Czechia
Patients applied
Trial Officials
Kateřina Jiroutková
Principal Investigator
3rd Faculty of Medicine, Charles University and FNKV, Prague
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported